Eli Lilly enters into USD 300m research partnership with Foghorn Therapeutics
Pharmaceutical firm Eli Lilly will pay USD 300m to collaborate with biotech company Foghorn Therapeutics on the development of novel oncology drugs. Another USD 80m will be given to Foghorn Therapeutics in the form of an equity investment by Eli Lilly.
by marketwire, translated by daniel pedersen
US-based pharmaceutical firm Eli Lilly has entered a strategic collaboration with biotech company Foghorn Therapeutics. Together, they will research new oncology targets, Eli Lilly announces in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
